close
close

Bispezifischer Antikörper verlängert laut Studie das Gesamtüberleben

Posted on by Vaseline
Bispezifischer Antikörper verlängert laut Studie das Gesamtüberleben


Dritte Interimsanalysis



The data from Phase III trial E1910 has initially – and highly – been published in full. Demnach increases the addition of blinatumomab to the effectiveness of a consolidation schedule therapy in MRD-negative treatment with B-Vorläufer-ALL.

Related Posts

TSV 1860 Munich – News

TSV 1860 Munich – News

The Karlsfelder Hotel Schwertfirm, since 2019 LöwenPartner, has extended its engagement a year later. The family experience has been an optimal atmosphere for the Munich […]